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with the complexity of the relationship between baseline antidepressant use and 
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relationship between baseline antidepressant use and hastened depressive recurrence 
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use in bipolar disorder longitudinal depressive burden.
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Highlights
Antidepressant use in Bipolar Depression is controversial
Antidepressants in Bipolar Depression can yield treatment-emergent manic switch 
(TEAMS)
Baseline antidepressant use was associated with TEAMS only if manic prior to 
depressive episodes were not censored
Thus, antidepressants have complex associations with longitudinal depressive burden 
in bipolar disorder
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Aims:  Antidepressant use is common in bipolar disorder (BD), but controversial due to 
questionable efficacy/psychiatric tolerability. We assessed associations between baseline 
antidepressant use and longitudinal depressive burden in BD. 
Methods: Stanford BD Clinic outpatients enrolled during 2000-2011 were assessed with 
the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders 
Evaluation and monitored longitudinally for up to two years with the STEP-BD Clinical 
Monitoring Form while receiving naturalistic expert treatment. Prevalence and clinical 
correlates of baseline antidepressant use in recovered (euthymic ≥8 weeks) and 
depressed patients were assessed. Kaplan-Meier survival analyses assessed times to 
depressive recurrence and recovery in patients with versus without baseline 
antidepressant use, and Cox Proportional Hazard regression analyses assessed covariate 
effects.
Results: Baseline antidepressant use was less among 105 recovered (31.4%) versus 153 
depressed (44.4%) patients (p=0.04), and among recovered patients was associated with 
Caucasian race, and higher rates of lifetime anxiety and eating disorders, and bipolar II 
disorder, earlier onset age, and worse Clinical Global Impression scores, and hastened 
depressive recurrence (only if mood elevation episodes were not censored), driven by 
lifetime anxiety disorder. Baseline antidepressant use among depressed patients was 
associated with older age, female gender, and higher anxiolytic and complex 
pharmacotherapy use rates, but no other unfavorable illness characteristic/current mood 
symptom, and not time to depressive recovery.
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Limitations: American tertiary BD clinic referral sample receiving open naturalistic expert 
treatment.
Conclusions: Additional research is required to assess the complex associations between 
baseline antidepressant use and longitudinal depressive burden in BD.
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Abstract: (246 words)
Aims:  Antidepressant use is common in bipolar disorder (BD), but controversial due to 
questionable efficacy/psychiatric tolerability. We assessed associations between baseline 
antidepressant use and longitudinal depressive burden in BD. 
Methods: Stanford BD Clinic outpatients enrolled during 2000-2011 were assessed with 
the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders 
Evaluation and monitored longitudinally for up to two years with the STEP-BD Clinical 
Monitoring Form while receiving naturalistic expert treatment. Prevalence and clinical 
correlates of baseline antidepressant use in recovered (euthymic ≥8 weeks) and 
depressed patients were assessed. Kaplan-Meier survival analyses assessed times to 
depressive recurrence and recovery in patients with versus without baseline 
antidepressant use, and Cox Proportional Hazard regression analyses assessed 
covariate effects.
Results: Baseline antidepressant use was less among 105 recovered (31.4%) versus 153 
depressed (44.4%) patients (p=0.04), and among recovered patients was associated with 
Caucasian race, and higher rates of lifetime anxiety and eating disorders, and bipolar II 
disorder, earlier onset age, and worse Clinical Global Impression scores, and hastened 
depressive recurrence (only if mood elevation episodes were not censored), driven by 
lifetime anxiety disorder. Baseline antidepressant use among depressed patients was 
associated with older age, female gender, and higher anxiolytic and complex 
pharmacotherapy use rates, but no other unfavorable illness characteristic/current mood 
symptom, and not time to depressive recovery.
Limitations: American tertiary BD clinic referral sample receiving open naturalistic expert 
treatment.
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Conclusions: Additional research is required to assess the complex associations between 
baseline antidepressant use and longitudinal depressive burden in BD.
Keywords: bipolar disorder; antidepressant; longitudinal; depression; illness 
characteristics.
Antidepressant Use & Bipolar Depressive Recurrence                   Hooshmand et al. Page 5
Introduction
Although antidepressants (with the exception of fluoxetine combined with olanzapine) are 
not FDA approved for treatment of bipolar disorder (BD)  (Ketter, 2015), they have been 
among the most common medications prescribed for treatment of BD, used twice as often 
as mood stabilizers (Baldessarini et al., 2007). The wide use of antidepressants in BD 
could be due to unmet pharmacological needs in treatment of depressive morbidity in BD 
(Frye et al., 2009; Goldberg, 2012; Kasper et al., 2008), as well as tolerability limitations of 
the three FDA-approved bipolar depression treatments, all of which have an antipsychotic 
component (Ketter, 2015; McIntyre et al., 2013).
Multiple previous studies do not support the efficacy of antidepressants in treatment of 
acute bipolar depression (Bauer et al., 2012; McElroy et al., 2010; Sachs et al., 2007; 
Sidor & Macqueen, 2011), and antidepressant monotherapy (i.e. without an antimanic 
agent) is commonly considered contraindicated in bipolar I disorder patients as well as 
certain bipolar II disorder patients due to concerns for increased risk of mood elevation 
and/or rapid cycling (Frye et al., 2009; Pacchiarotti et al., 2013; Prien et al., 1984; Vieta, 
2005).  Attributing the direction of causality between antidepressant use and emergence of 
hypomanic, manic, and mixed states, rapid cycling, and depression itself remains 
controversial because of the highly variable natural course of BD which makes it difficult to 
distinguish spontaneous from antidepressant-induced mood changes (Licht et al., 2008) 
and associations of mixed and rapid cycling presentations with treatment-resistant 
depression which could itself result in antidepressant administration.  
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Although available data support faster short-term recovery from depression with the 
olanzapine-fluoxetine combination (Tohen et al., 2003), other studies show highly variable 
acute and longer-term effects when antidepressants are used (either as monotherapy or in 
combination with mood stabilizers) for the treatment of bipolar depression (Altshuler et al., 
2017; Ghaemi et al., 2008; Goldberg et al., 2007; McElroy et al., 2010; Sachs et al., 2007; 
Sidor & Macqueen, 2011).
Data on the efficacy and tolerability of long-term use of antidepressants in BD are 
inadequate, with some (but not all) studies suggesting that adjunctive antidepressant use 
is associated with increased switch to mania/hypomania and only variable protection from 
depression (Amsterdam et al., 2015; Ghaemi et al., 2008). Other studies have reported 
increased depressive recurrence with longer-term antidepressant treatment (Ghaemi et 
al., 2004; Sachs et al., 2007). In contrast, one observational study found that among the 
limited percentage (approximately 15%) of BD patients who initially uneventfully (i.e., 
without emergence of mood elevation symptoms) remitted from a major depressive 
episode while taking antidepressants added to mood stabilizers, those who continued 
compared to those who discontinued antidepressants within 6 months of remission had an 
approximately 50% lower rate of depressive recurrence (Altshuler et al., 2003; Amsterdam 
et al., 2015; Pacchiarotti et al., 2013). Indeed, although the International Society for BD 
guidelines for the short-term treatment of bipolar depression appear clinically useful, the 
potential role of antidepressants in the longer-term management of BD remains to be 
established (Tundo et al., 2015).
In summary, the association between antidepressant use and illness course remains 
controversial in BD. In this prospective study, we examined longitudinal relationships 
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between baseline antidepressant use and episode recurrence and recovery in BD 
patients.
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Methods
Outpatients referred to the Stanford BD Clinic from 2000 to 2011 were assessed using the 
Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation 
(Sachs et al., 2002; Sachs et al., 2003), which included the Structured Clinical Interview for the 
fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (SCID for DSM-IV) 
(First et al., 1997) mood disorders module and the Clinical Global Impression for BD-Overall 
Severity (CGI-BP-OS) score (Spearing et al., 1997). The Mini International Neuropsychiatric 
Interview (MINI) (Sheehan et al., 1998) was also performed in order to confirm bipolar and 
comorbid psychiatric disorder diagnoses. Patients were followed prospectively for up to two 
years, while receiving naturalistic expert-administered treatment with a monthly modal visit 
frequency. The Clinical Monitoring Form (CMF) (Sachs et al., 2002) was used to assess clinical 
status at each follow-up visit. 
Current (baseline) medication use was based upon patient report and review of medical 
records at the time of enrollment. Antidepressants included Selective Serotonin Reuptake 
Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Atypical 
Antidepressants (AAs, e.g., bupropion, mirtazapine), and First-Generation Antidepressants 
(FGAs, e.g., heterocyclic antidepressants, monoamine oxidase inhibitors). Mood stabilizers 
included lithium, valproate, carbamazepine, and lamotrigine. Antipsychotics included the Second-
Generation agents olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole. 
Anxiolytic/hypnotics included benzodiazepine and non-benzodiazepine agents administered for 
anxiety (e.g., lorazepam, clonazepam, alprazolam, and buspirone) and/or insomnia (e.g., 
temazepam, zolpidem, and trazodone). 
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As described below, clinical characteristics of participants were evaluated and prospective 
clinical course of participants meeting diagnostic criteria for either current recovery (euthymic ≥ 8 
weeks) or a current major depressive episode at enrollment were assessed for the primary 
analyses. Secondary analyses included assessment of participants experiencing a current 
manic/hypomanic/mixed episode. The Stanford University Administrative Panel on Human 
Subjects approved the STEP-BD protocol, as well as the subsequent similar Assessment, 
Monitoring, and Centralized Database protocol specific to Stanford University. Both protocols 
conformed to the standards of the Helsinki Declaration as revised in 1989, and all subjects 
provided verbal and written informed consent before participating in the study.
Trained medical and research staff collected data on 6 demographic parameters and 25 
illness characteristics/current mood symptoms/current (baseline) medications. The demographic 
parameters assessed were: (A) Age (in years); (B) Gender; (C) Race/Ethnicity; (D) Education; (E) 
Marital Status; and (F) Employment status. The illness characteristics/current mood 
symptoms/current (baseline) medications assessed were: (1) Lifetime anxiety disorder; (2) 
Lifetime alcohol/substance use disorder; (3) Lifetime eating disorder; (4) Lifetime personality 
disorder; (5) Bipolar II Disorder; (5A) Lifetime psychosis (which is very commonly associated with 
Bipolar I Disorder); (5B) Lifetime prior psychiatric hospitalization (which is also very commonly 
associated with Bipolar I Disorder); (6) ≥ One first-degree relative with mood disorder; (7) Onset 
age (in years); (8) Childhood (age < 13 years) onset; (9) Illness duration (in years); (10) Long 
illness duration (≥ 15 years); (11) Episode accumulation (≥ 10 prior mood episodes); (12) Lifetime 
suicide attempt; (13) Rapid cycling (≥ 4 episodes) in prior year; (14) current CGI-BP-OS; current 
(i.e., any in the prior 10 days); (15) Sadness; (16) Anhedonia; (17) Euphoria; (18) Irritability; and 
(19) Anxiety; and current (baseline) (20) Mood stabilizer use; (21) Antipsychotic use; (22) 
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Antidepressant use; (23) Anxiolytic/Hypnotic use; (24) Complex Pharmacotherapy (≥ 4 mood 
stabilizers, antipsychotics or antidepressants); and (25) Number of Core Psychotropics (mood 
stabilizers, antipsychotics, antidepressants).
Statistical analyses were performed using Statistical Package for the Social Sciences 
(SPSS) Version 23.0 software (IBM Corp.; Armonk, NY) on an Apple MacBook Air computer 
(Apple Corporation, Cupertino, CA). Prevalence and clinical correlates of baseline antidepressant 
use were examined in currently recovered (i.e., euthymic ≥ 8 weeks) and currently depressed 
(i.e., with a current major depressive episode) patients, as well as patients experiencing a current 
mood elevation (manic/hypomanic/mixed) episode. Analytical statistics included Fisher’s Exact 
test comparisons of categorical data and independent-sample t-test comparisons of continuous 
variables. In addition, binary logistic regression was used to adjust for potential confounding 
variables. 
Primary longitudinal analyses consisted of Kaplan-Meier survival analyses (Log-Rank 
tests), which compared times to depressive recurrence and recovery in patients with and without 
baseline antidepressant use. We used for the primary recurrence analyses the novel approaches 
of not censoring patients with mood elevation episode prior to depressive episode recurrence in 
assessing time to depressive recurrence, and not censoring patients with depressive episode 
prior to mood elevation episode recurrence in assessing time to mood elevation recurrence, and 
for secondary recurrence analyses the more conventional approaches of censoring patients with 
mood elevation prior to depressive recurrence in assessing time to depressive recurrence, and 
censoring patients with depressive prior to mood elevation recurrence in assessing time to mood 
elevation recurrence (Tohen et al., 1990). We used for the primary recovery analyses the novel 
approaches of not censoring patients with mood elevation episode prior to depressive episode 
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recovery in assessing time to depressive episode recovery, and not censoring patients with 
depressive episode prior to mood elevation episode recovery in assessing time to mood elevation 
recovery, and for secondary analysis, the more conventional approaches of censoring patients 
with mood elevation episode prior to depressive episode recovery in assessing time to 
depressive recovery, and censoring patients with depressive episode prior to mood elevation 
episode recovery in assessing time to mood elevation recovery. Secondary metrics included for 
baseline antidepressant use and depressive longitudinal severity were Kaplan-Meier estimated 
recurrence/recovery rates for significant longitudinal depressive associations. Additional 
secondary analyses included Cox proportional hazard analyses (hazard ratios (HRs) and 95% 
confidence intervals (CIs)) of depressive recurrence and recovery, as well as of potential 
mediators of statistically significant longitudinal depressive illness severity findings. To select 
parameters for entry into mediator models, univariate Cox proportional hazard analyses were 
performed for all statistically significant clinical correlates of current antidepressant use. 
Parameters with p < 0.05 were entered into a forward stepwise procedure, and covariates were 
included in the model if p < 0.05. Additionally, Cox proportional hazard analyses with time-
dependent covariates were used to further characterize associations between current 
antidepressant use and depressive recurrence and recovery. Finally, among recovered patients, 
we assessed changes from baseline to depressive recurrence/endpoint (last visit if no 
recurrence) in antidepressant status (i.e. numbers of patients continuing same antidepressants, 
switching antidepressants, and discontinuing antidepressants). Throughout analyses, we used a 
two-tailed significance threshold with p < 0.05, with no correction for multiple comparisons. 
Results
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Table 1 includes demographics, illness characteristics, current mood symptoms, and 
baseline medications in currently recovered and currently depressed BD outpatients, stratified by 
the presence or absence of baseline antidepressant use. In our overall sample of 503 outpatients 
with bipolar I disorder or bipolar II disorder, 105 (20.9%) were currently recovered and 153 
(30.4%) were currently depressed. The prevalence of baseline antidepressant use was 
significantly lower among recovered versus depressed (31.4% versus 44.4%, Chi-square = 4.4, 
df = 1, p = 0.04) patients.
Demographics and Illness Characteristics/Current Mood Symptoms/Baseline Medications 
in Recovered Patients With Versus Without Baseline Antidepressant Use.
Among recovered patients, presence compared to absence of baseline antidepressant use 
was significantly less common by more than one-half (31.4% versus 68.6% were and were not 
currently taking antidepressants, respectively, Binomial test p = 0.0002). Indeed, recovered 
patients with versus without baseline antidepressant use had significantly higher rates of 
Caucasian race (90.9% versus 69.4%, Chi-square = 5.3, df = 1, p = 0.02), lifetime anxiety (69.7% 
versus 36.1%, Chi-square = 10.3, df = 1, p = 0.002), and eating (21.2% versus 4.2%, Chi-square 
= 7.6, df = 1, p = 0.01) disorders, bipolar II disorder (57.6% versus 30.6%, Chi-square = 6.9, df = 
1, p = 0.01), and baseline antidepressant use (by definition, 100.0% versus 0.0%, Chi-square = 
105.0, df = 1, p < 0.0001), as well as significantly lower mean  SD onset age (16.9  8.3 versus 
20.6  9.0, t = -2.0, df = 102, p = 0.046), and significantly higher CGI-BP-OS scores (2.4  0.8 
versus 2.1  0.8, t = 2.3, df = 103, p = 0.02), and number of core psychotropics used (partially by 
definition, 2.4 ± 0.8 versus 1.3 ± 0.8, t = 6.5, df = 103, p < 0.0001).  Although baseline 
antidepressant use was inversely associated with history of psychiatric hospitalization (24.2% 
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versus 56.9%, Chi-square = 9.7, df = 1, p = 0.003) rate, this relationship was mediated by the 
association of bipolar I subtype with history of psychiatric hospitalization. All of the above-
mentioned significant relationships between baseline antidepressant use and other illness 
characteristics/current mood symptoms/baseline medications in recovered patients remained 
significant after covarying for race. No other demographic parameter and no other clinical 
characteristic in Table 1 was significantly associated with baseline antidepressant use among 
recovered patients.
INSERT TABLE 1 ABOUT HERE
Demographics and Illness Characteristics/Current Mood Symptoms/Baseline 
Medications in Depressed Patients With Versus Without Baseline Antidepressant Use.
Among currently depressed patients, presence compared to absence of baseline 
antidepressant use was only non-significantly less common (44.4% versus 55.6% had and lacked 
baseline antidepressant use, respectively, Binomial test p = 0.20). Nevertheless, baseline 
antidepressant use was significantly associated with a higher mean ± SD age (38.8  13.7 versus 
34.1  12.8, t = 2.2, df = 151, p = 0.03) and rate of female gender (72.1% versus 52.9%, Chi – 
square = 5.8, df=1, p = 0.02), as well as significantly higher rates of baseline antidepressant (by 
definition, 100.0% versus 0.0%, Chi-Square = 153.0), df = 1, p < 0.0001), anxiolytic/hypnotic 
(50.2% versus 22.4%, Chi-square = 12.8, df=1, p = 0.0006), and complex pharmacotherapy 
(partially by definition, 42.6% versus 17.6%, Chi-square = 18.6, df=1, p < 0.0001) use, as well as 
more core psychotropics used (partially by definition, 2.3 ± 1.1 versus 1.1 ± 1.1, t = 6.7, df = 151, 
p < 0.0001). No other demographic parameter and no illness characteristic in Table 1 was 
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significantly associated with baseline antidepressant use among depressed patients. Higher rates 
of baseline anxiolytic/hypnotic and complex pharmacotherapy use in depressed patients with 
versus without baseline antidepressant use were driven by age, but not by gender. In contrast, no 
demographic drove the higher number of core psychotropics in patients with versus without 
baseline antidepressant use. No illness characteristic drove higher rates of anxiolytic or complex 
pharmacotherapy use, or higher number of core psychotropics in depressed patients with versus 
without baseline antidepressant use.}
Baseline Antidepressant Use in Relationship to Time to Recurrence.
Baseline antidepressant use was significantly associated with hastened depressive 
recurrence (Log-Rank p = 0.033) in 33 vs. 72 recovered patients with versus without baseline 
antidepressant use, only if the 3 (9.1%) versus 16 (22.2%) with mood elevation episodes prior to 
depressive episode recurrence were not censored (Figure 1). Indeed, censoring patients with 
mood elevation episodes prior to depressive episode recurrence reduced the relationship 
between baseline antidepressant use and hastened depressive recurrence to a trend-level (Log-
Rank p = 0.08).
Insert Figure 1 About Here
Baseline antidepressant use was also associated with hastened depressive recurrence 
using Cox Proportional Hazard analysis (HR = 1.9; 95% CI 1.0-3.5; p = 0.036), once again only if 
mood elevation episode prior to depressive episode recurrence were not censored. Hastened 
depressive recurrence among patients with baseline antidepressant use was driven by lifetime 
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anxiety disorder (HR = 2.8; 95% CI 1.4 - 5.4; p = 0.003). However, the Kaplan-Meier estimated 
depressive recurrence rate was only non-significantly higher among patients with (70.3%; 95% CI 
52.5 - 88.1) compared to without (42.7%; 95% CI 28.8 - 56.6) baseline antidepressant use.
In contrast, baseline antidepressant use only non-significantly tended to be associated 
with time to mood elevation recurrence (Log-Rank p > 0.05 and < 0.10) in 33 vs. 72 recovered 
patients with versus without baseline antidepressant use, whether or not depressive episodes 
were censored (not illustrated). Also, baseline antidepressant use was not significantly 
associated with time to any mood episode recurrence (Log-Rank p = 0.70) in 33 vs. 72 recovered 
patients with versus without baseline antidepressant use (not illustrated).
Among recovered patients taking baseline antidepressants with (N = 24) versus without (N 
= 9) antimanic (second-generation antipsychotics, lithium, valproate, and carbamazepine (but 
NOT lamotrigine)) agents, times to depressive (with or without censoring prior mood elevation 
episodes) and mood elevation (with or without censoring prior depressive episodes) recurrence 
were not significantly different. 
Baseline Antidepressant Use in Relationship to Time to Recovery.
Baseline antidepressant use was not significantly related to time to recovery whether or 
not opposite pole mood episode prior to recovery was censored in 68 vs. 85 depressed patients 
with versus without baseline antidepressant use, and in 13 versus 41 manic/hypomanic/mixed 
patients with versus without baseline antidepressant use (not illustrated). Also, times to recovery 
from any mood episode, in 81  versus 126 syndromal mood episode patients with versus without 
baseline antidepressant use were not significantly different (not illustrated).  
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  Among patients taking baseline antidepressants with versus without antimanic agents, 
times to recovery from depression (N = 45 and 23, respectively; with or without censoring mood 
elevation) and from mood elevation (N =12 and 1, respectively; with or without censoring 
depression) were not significantly different (not illustrated). Also, among patients taking baseline 
antidepressants with (N = 57) versus without (N = 24) antimanic agents, times to recovery from 
any mood episode (without censoring mood elevation or depression prior to recovery) were not 
significantly different (not illustrated). 
Antidepressant Changes in Recovered Patients With and Without Depressive 
Recurrence.
Among recovered patients taking baseline antidepressants with depressive recurrence (20/33, 
60.6%), longitudinal antidepressant use included: continuation of same antidepressant (14/20, 
70.0%), discontinuation of antidepressant (5/20, 25%), and switch to a different 
antidepressant (1/20, 5.0%).  Of note, among 5/20 (25%) recovered patients taking 
antidepressants with a depressive recurrence who had a mood elevation episode prior to the 
depressive episode; continuation of same antidepressant was observed in 3/5 (60.0%), while 
antidepressant was discontinued in 2 (40.0%) of these patients. Among recovered patients 
taking antidepressants without depressive recurrence (13/33, 39.4%), longitudinal 
antidepressant use included: continuation of same antidepressant (10/13, 76.9%) and switch 
to a different antidepressant (3/13, 23.1%).
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Discussion
We found that among recovered patients, baseline antidepressant use was 
significantly associated with Caucasian race, lifetime anxiety and eating disorders, bipolar 
II disorder, worse CGI score, lower onset age, more core psychotropic use, and hastened 
depressive recurrence (only if prior mood elevation episodes were not censored); driven 
by lifetime anxiety disorder. Baseline antidepressant use only non-significantly tended to 
be associated with time to mood elevation recurrence (whether or not depressive episodes 
were censored). Also, baseline antidepressant use with or without antimanic agents 
yielded no significant difference in times to recurrence of depression and mood elevation 
(with or without censoring mood elevation episodes and depressive episodes, 
respectively). In addition, baseline antidepressant use (with or without antimanic agents) 
was not significantly associated with time to recovery from depressive or 
manic/hypomanic/mixed or any mood episode.  
Our finding of hastened depressive recurrence among recovered patients taking 
antidepressants is novel. Although antidepressant use has previously been associated 
with moderately reduced risk of depressive recurrence (Ghaemi et al.; 2008), it has also 
been associated with increased risk of switch to mania/hypomania. However, 
antidepressant use has not previously been significantly associated with hastened 
depressive recurrence (Amsterdam et al.; 2015,Ghaemi et al.; 2008, Pacchiarotti et al., 
2013; Sidor & Macqueen, 2011; Truman et al., 2007 or Bowden et al. 2011), although 
discontinuation of antidepressants soon after remission has been related to increased 
depressive recurrence in the 15% of BD patients with very good acute antidepressant 
responses (Altshuler et al., 2003).
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Furthermore, we found that lifetime anxiety disorder, which has been associated 
with greater risk of depressive recurrence (Perlis et al., 2006; Shah et al., 2017) was a 
driver of hastened depressive recurrence in patients taking baseline antidepressants. Also, 
our finding of hastened depressive recurrence in patients taking baseline antidepressants 
was significant only if prior mood elevation episodes were not censored, highlighting the 
importance of assessing causality in the relationship between antidepressant use and the 
risk of mood elevation after depression (Pacchiatotti et al., 2013).
In our study, antidepressant use (with or without anti-manic agents) was only non-
significantly associated with mood elevation recurrence despite the previously observed 
increase in risk of mania related to antidepressant use (Ghaemi et al., 2008).  However, 
available data on association of antidepressant mood switches into 
manic/hypomanic/mixed states remains highly variable which might be related to use of 
different definitions of switching (e.g., YMRS (Young Mania Rating Scale) score greater 
than 8 versus 15) in different studies (Calabrese et al. 1999), differences in switch rates in 
bipolar I disorder versus bipolar II disorder (Amsterdam et al., 2015, Bond et al., 2008), 
use of different classes of antidepressants (Post et al. 2001; Vieta et al. 2002), and 
difficulty in distinguishing spontaneous from antidepressant induced switching (Licht et al., 
2008). In our study, antidepressants were used more frequently in depressed than 
recovered patients and in recovered patients with certain unfavorable illness 
characteristics (e.g., earlier onset age and worse CGI score), highlighting the need for 
greater understanding of how more severe BD with worse long-term outcomes could result 
in antidepressant use.
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In contrast, in our study, current antidepressant use was not significantly associated 
with time to depressive recovery, potentially consistent with the previously observed lack 
of efficacy of antidepressants for acute treatment of bipolar depression (Sidor & 
Macqueen, 2011). Except for acute use of the combination of olanzapine/fluoxetine, which 
is FDA-approved for treatment of acute bipolar depression (Tohen et al. 2003), and a 
systematic review and meta-analysis of 12 randomized controlled trials published by 
Gijsman and colleagues in 2004 (which was substantially influenced by the above study) 
that showed antidepressants were efficacious and safe for treatment of bipolar depression, 
most controlled studies suggest antidepressants lack efficacy for acute treatment of 
bipolar depression (Sachs et al. 2007; Sidor & Macqueen, 2011). This may be even more 
the case for mixed bipolar depression. Indeed, among STEP-BD patients with mixed 
depression, adjunctive antidepressant treatment neither hastened nor slowed depressive 
recovery (Goldberg et al. 2007). Nevertheless, in a recent reanalysis of STEP-BD data by 
Tada, et al. in 2015, using higher doses of antidepressants added to mood stabilizers 
yielded greater clinical improvement without increasing risk of switch to mania, pointing to 
the need for further research into the potential utility of antidepressants for bipolar 
depression (Tada et al., 2015). 
We found that antidepressant administration was related to 5 illness characteristics 
(lifetime anxiety disorder, lifetime eating disorder, bipolar II disorder, earlier onset age, and 
worse CGI-BP-OS) among recovered patients, but none among depressed patients. This 
difference was consistent with the notion that administration of antidepressants to 
recovered versus depressed BD patients may entail more potential illness characteristic 
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confounds/mediators. Indeed, we found that lifetime anxiety disorder drove hastened 
depressive recurrence among recovered patients with baseline antidepressant use. 
Our study has the strengths of assessing relationships between current antidepressant 
use and not only hastened depressive recurrence but also delayed depressive recovery, 
using validated instruments to assess diagnosis and longitudinal course, and having 
substantial numbers of both well-characterized recovered (N = 105) and depressed (N = 153) 
BD patients. Furthermore, our rates of depressive recurrence and recovery were comparable 
to those found in other studies (Vazquez et al. 2015; Otto et al. 2006; Perlis et al. 2006). 
However, these strengths are accompanied by limitations that include the use of a sample 
referred to a suburban Northern California BD specialty clinic, limiting the generalizability of 
our findings in our relatively affluent, well educated but relatively underemployed, 
predominantly female sample of BD patients with medical insurance, rather than a more 
heterogeneous mixture of BD inpatients and outpatients being treated in non-specialty clinical 
settings. Additionally, our sample size, though substantial, had insufficient statistical power to 
be able to adequately assess relationships between baseline antidepressant use and times to 
mood elevation recurrence/recovery. In addition, our significant finding of current 
antidepressant use hastening depressive recurrence could be related to subsequent mood 
elevation episodes leading to depression, as our significant finding became only a trend when 
patients with prior manic, hypomanic, and mixed episodes were censored. Additional 
limitations included: (1) medications being changed during treatment (although our 
calculations indicated effects of this phenomenon were likely limited); (2) not being able to 
determine causality regarding the association of antidepressant administration with hastened 
depressive recurrence (i.e., whether antidepressant administration directly hastened 
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depressive recurrence, or depression/anxiety prone illness resulted in both hastened 
depressive recurrence and antidepressant administration, although we hypothesize the latter); 
(3) potentially heterogeneous reasons for antidepressant administration (e.g., for anxiety 
versus depression); (4) among recovered patients, we didn’t know whether or not 
antidepressants yielded recovery from the most recent depressive episode or antidepressant 
withdrawal yielded depressive recurrence; (5) the controversial phenomenon of 
antidepressant treatment emergent mood elevation was beyond the scope of this paper. 
Furthermore, mood episode/recovered status duration prior to enrollment was not included in 
our analyses of mood episode recurrence and recovery. Another limitation was the open 
naturalistic treatment design, in which patients received diverse uncontrolled (albeit expert-
selected, guideline-informed, measurement- and evidence-based) therapies. Finally, we did 
not correct for multiple comparisons, which particularly limited interpretation of findings with p-
values between 0.05 and 0.01. However, this liberal statistical approach increased assay 
sensitivity with respect to our ability to detect relationships between baseline antidepressant 
use and depressive recurrence and recovery. 
Nevertheless, we contend that our observation of an association between baseline 
antidepressant use and hastened depressive recurrence suggests an important relationship 
between baseline antidepressant use and longitudinal depressive burden in BD. Given the 
commonly inadequate outcomes associated with bipolar depression and antidepressant use, 
further examination of this relationship is warranted in order to better understand mechanisms 
and clinical implications. 
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Figure Legend
Figure 1. Baseline Antidepressant Use Associated with Hastened Depressive 
Recurrence in Bipolar Disorder.
Two-year survival analysis of time to depressive recurrence in recovered bipolar disorder 
patients indicated significantly hastened depressive recurrence in patients with (N = 33, 
black line on bottom) versus without (N = 72, gray line on top) current antidepressant use 
(Log-Rank p = 0.033), only if the 3 (9.1%) versus 16 (22.2%) patients with mood elevation 
episodes prior to depressive episode recurrence were not censored. Baseline 
antidepressant use was also associated with hastened depressive recurrence using Cox 
Proportional Hazard analysis (HR = 1.9; 95% CI 1.0-3.5; p = 0.036), once again only if 
mood elevation episode prior to depressive recurrence were not censored. Hastened 
depressive recurrence among patients with baseline antidepressant use was driven by 
lifetime anxiety disorder (HR = 2.8; 95% CI 1.4 - 5.4; p = 0.003).

Table 1. Demographics, Illness Characteristics, Current Mood Symptoms, and Baseline 
Medications in Currently Recovered and Currently Depressed BD Outpatients With Versus 
Without Baseline Antidepressant Use. 
 
Recovered  
w AD
Recovered 
w/o AD
Depressed 
w AD
Depressed 
w/o AD
N (%) 33 (31.4)^*** 72 (68.6) 68 (44.4) 85 (55.6)
Demographics     
A. Age (years, mean ± SD) 37.0±13.1 35.7 ± 14.0 38.8 ± 13.7* 34.1 ± 12.8
B. Female (%) 60.6 52.8 72.1* 52.9
C. Caucasian (%) 90.9* 69.4 92.6 82.4
D. College degree (%) 69.7 61.1 55.9 40.0
E. Married (current, %) 33.3 37.5 39.7 35.3
F. Full time Employment (current, %) 24.2 37.5 22.1 28.6
Comorbid Disorders (lifetime, %)     
1. Anxiety 69.7** 36.1 72.1 81.2
2. Alcohol/Substance Use 51.5 50.0 57.4 58.8
3. Eating 21.2* 4.2 17.6 20.0
4. Personality 9.1 8.3 11.8 16.5
Other Illness Characteristics     
5. Bipolar II disorder (%) 57.6* 30.6 67.6 56.5
5A. Psychosis (lifetime, %) 33.3 52.8 38.2 34.1
5B. Psychiatric Hospitalization (lifetime, %) 24.2** 56.9 27.9 24.7
6. ≥ One 1° Relative w Mood Disorder (%) 60.6 40.3 63.2 56.5
7. Onset age (years, mean ± SD) 16.9± 8.3* 20.6 ± 9.0 18.0 ± 8.7 16.4 ± 6.9
8. Childhood (age <13 years) Onset (%) 18.2 8.3 22.1 23.5
9. Illness Duration (years, mean ± SD) 16.6 ± 11.3 17.8 ± 14.4 20.4 ± 13.9 17.4 ± 12.4
10. Long Illness Duration (≥ 15 years, %) 54.5 43.1 56.7 50.6
11. Episode accumulation (≥ 10, lifetime, %) 57.6 38.9 72.7 71.1
12. Suicide Attempt (lifetime, %) 33.3 22.2 40.3 29.4
13. Rapid Cycling (≥ 4 episodes in prior year, %) 6.1 11.1 26.9 31.0
14. CGI-BP-OS (current, mean ± SD) 2.4 ± 0.8* 2.1 ± 0.8 5.4 ± 0.8 5.3 ± 0.7
Mood Symptoms (any in prior 10 days, %)     
15. Sadness 21.2 18.1 91.2 88.2
16. Anhedonia 15.2 13.9 95.6 94.1
17. Euphoria 21.2 9.7 29.4 27.1
18. Irritability 42.4 33.3 63.2 72.9
19. Anxiety 45.5 31.9 80.9 81.2
Medication Use (current)     
20. Mood Stabilizer (MS, %) 75.8 72.2 67.647 55.300
21. Antipsychotic (AP, %) 39.4 34.7 39.706 30.600
22. Antidepressant (AD, %) 100.0**** 0.0 100.0**** 0.0
23. Anxiolytic/Hypnotic (AN, %) 21.2 15.3 50.0*** 22.4
25. Complex Pharmacotherapy (≥ 4 MS, AP, AD, %) 24.2 16.7 42.6**** 17.6
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26. Number of Core Psychotropics (MS, AP, AD, mean ± SD) 2.4 ± 0.8**** 1.3 ± 0.8 2.3 ± 1.1**** 1.1 ± 1.1
AD indicates baseline Antidepressant use; CGI-BP-OS indicates Clinical Global Impression for 
Bipolar Disorder-Overall Severity; SD indicates standard deviation; w indicates with; w/o indicates 
without.
Boldface font indicates parameters with statistically significant relationships with current 
antidepressant use not dependent on bipolar subtype. Italic font indicates parameter related to 
bipolar I disorder
Missing data: Recovered: 12.4% for ≥ 10 prior episodes, 0.0%-4.8% for other parameters; 
Depressed: 7.2% for ≥ 10 prior episodes, 0.0%-1.3% for other parameters.
^ p <0.05 Recovered w AD vs Depressed w AD.
* p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 w vs w/o AD.
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